Synthetic pineal tetrapeptide (longevity bioregulator)
A synthetic 4-amino-acid peptide modeled on the natural pineal polypeptide epithalamin; studied for anti-aging.
| Class / type | Synthetic pineal tetrapeptide (longevity bioregulator) |
|---|---|
| Category | Longevity & Cellular |
| Status (Jul 2026) | Research use only |
Epithalon (Epitalon) is a synthetic four-amino-acid peptide modeled on epithalamin, a natural substance from the pineal gland. Developed by Russian researcher Vladimir Khavinson, it's one of the most discussed 'longevity' peptides.
It is not FDA-approved and is sold as a research chemical; the science, while decades old, is concentrated in one research lineage.
Two effects are proposed: activation of telomerase (the enzyme that maintains telomeres, the protective caps on chromosomes that shorten with age) and restoration of pineal function to normalize melatonin secretion and circadian rhythm.
There's in-vitro evidence of telomerase activation and telomere elongation in human cells, rodent studies reporting lifespan extension and reduced tumors, and long-term Russian cohort work associating use with better markers and lower mortality. Independent Western replication is scarce, so quality is limited.
Reported improvements in sleep quality and a general 'systemic anti-aging' feeling; the telomere/longevity rationale and a long (if narrow) research history drive strong interest.
Generally described as well tolerated in the available studies.
Human evidence is limited and concentrated in one research group. Telomerase activation raises a theoretical cancer concern (though studies reported fewer tumors, not more).
Long-term safety isn't established by modern standards, and gray-market purity is a concern.
Research-use-only in the US. In July 2026 an FDA advisory panel voted to recommend it (as Epitalon) for compounding, but that vote is advisory and not yet final. Often run in short cyclical 'courses' in community protocols, though no dosing is sanctioned.
Improved sleep quality and a general 'systemic anti-aging' feeling; telomere/longevity narrative.
NOT FDA-approved; research-use-only. On Jul 24, 2026 the FDA's PCAC voted to recommend it (as Epitalon) for 503A compounding (advisory only); no final rule yet. The next step is formal FDA rulemaking with a public comment period, and the FDA may allow interim enforcement discretion in the meantime. Verify.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.